Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
Published Online: 2019-09-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: A Anand•A Capp•A Colombo•A Ferrero•A Slot•A Snyers•A Stewart•Amanda Feeney•Andrea Lissoni•Anthony Fyles•B Van Triest•C Davidson•C Johnson•CM McLachlin•Carien L Creutzberg•Chantal Hanzen•Christine Haie-Meder•D Berton-Rigaud•D Gregory•Diane Provencher•Dionyssios Katsaros•E Pras•EM Van der Steen-Banasik•G Artioli•G Thomas•GH Westerveld•Godfrey Wilson•H Hollema•Hans W Nijman•Hein Putter•Henry C Kitchener•I Kolodziej•Ina M Jürgenliemk-Schulz•J Pyman•JJ Jobsen•JM Mens•Jonathan A Ledermann•K Whitmarsh•KAJ De Winter•Karen W Verhoeven-Adema•L Souhami•LCHW Lutgens•Linda Mileshkin•M Adusumalli•M McCormack•MA Quinn•Marie-Helene Baron•Melanie E Powell•N Tubiana-Mathieu•Naveena Singh•P Duvillard•P Ghatage•P Symonds•PJ Hoskin•PVC Rittenberg•Paul Bessette•Pearly Khaw•Petronella B Ottevanger•R Allerton•R Fossati•R Wade•Remi A Nout•Romerai D'Amico•Roy F Kruitwagen•S Carinelli•Sergio Gribaudo•Stephanie M de Boer•Susan Brooks•TC Stam•Viet Do•Vincent T H B M Smit•W Taylor
